# BiGEN

> BiGEN is a VC fund in Seoul backing Biotechnology, Medical and App Discovery. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 4
- Last investment: Mar 2021
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://bi-gen.com/

BiGEN is a biotech company with the goal of providing qualified medicinal products.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| App Discovery | 1 | 25% |
| Product Research | 1 | 25% |
| Contact Management | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 75% |
| Series C | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Noile-Immune Biotech | Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy. | $21.9M | Series C | Mar 22, 2021 |  |
| Junten Bio | JUNTEN BIO is a company is to develop new technologies in the field of regenerative medicine. | $1.8M |  | Dec 17, 2018 |  |
| Noile-Immune Biotech | Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy. | $77K |  | May 31, 2018 |  |
| Momotaro-Gene | Momotaro-Gene is a drug discovery business for commercialization of drug discovery seeds. | $1.4M |  | Mar 15, 2017 |  |

4 of 4 investments shown.

## Co-investors
- [DCI Partners](https://shizune.co/investors/profile/dci-partners) — VC Fund, 3 deals together
- [Sosei CVC](https://shizune.co/investors/profile/sosei-cvc) — VC Fund, 2 deals together
- Binex — VC Fund, 1 deal together
- [Dai-ichi Life](https://shizune.co/investors/profile/dai-ichi-life) — VC Fund, 1 deal together
- Healthcare Innovation — VC Fund, 1 deal together
- [H.U. Group Central Research Institute](https://shizune.co/investors/profile/h-u-group-holdings) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does BiGEN invest in?

BiGEN invests primarily in Biotechnology, Medical and App Discovery startups, most often at Funding Round and Series C stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did BiGEN last invest?

The most recent investment recorded for BiGEN closed in Mar 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co